Related Experiment Video
Updated: Aug 7, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Denise K Walters1, Thomas Mercher, Ting-Lei Gu
1Howard Hughes Medical Institute, Portland, Oregon 97239, USA.
Abstract:
Tyrosine kinases are aberrantly activated in numerous malignancies, including acute myeloid leukemia (AML). To identify tyrosine kinases activated in AML, we developed a screening strategy that rapidly identifies tyrosine-phosphorylated proteins using mass spectrometry. This allowed the identification of an activating mutation (A572V) in the JAK3 pseudokinase domain in the acute megakaryoblastic leukemia (AMKL) cell line CMK. Subsequent analysis identified two additional JAK3 alleles, V722I and P132T, in AMKL patients. JAK3(A572V), JAK3(V722I), and JAK3(P132T) each transform Ba/F3 cells to factor-independent growth, and JAK3(A572V) confers features of megakaryoblastic leukemia in a murine model. These findings illustrate the biological importance of gain-of-function JAK3 mutations in leukemogenesis and demonstrate the utility of proteomic approaches to identifying clinically relevant mutations.
Related Concept Videos
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Differentiation of Common Myeloid Progenitor Cells
PI3K/mTOR/AKT Signaling Pathway

